Cambridge Innovation Capital

Cambridge Innovation Capital
Name	Cambridge Innovation Capital
Type	Venture capital
Founded	2013
Founders	Anton Howes; Simon King; Hermann Hauser
Headquarters	Cambridge, England
Products	Venture capital funds, seed and growth equity
Assets	£x (estimate)

Cambridge Innovation Capital is a venture capital firm based in Cambridge, England, focused on early-stage and growth-stage investments in science and technology companies originating from the University of Cambridge, Cambridge Cluster, and related research institutions. The firm operates in the context of the United Kingdom investment landscape and collaborates with technology transfer offices, corporate partners, and academic incubators to commercialize research in life sciences, deep technology, and synthetic biology. Investors and portfolio companies often include participants from the Silicon Fen ecosystem, the European Investment Bank, and strategic corporate backers.

History

Cambridge Innovation Capital was founded in 2013 amid a wave of venture formation in the Cambridge Cluster, with roots connecting to collaborators such as Hermann Hauser and alumni of the University of Cambridge. Early activity occurred alongside local initiatives like IdeaSpace and incubators associated with Addenbrooke's Hospital and the Cambridge Science Park. The firm grew during the same period that high-profile exits and listings—such as companies from Cambridge Antibody Technology alumni and spinouts from Illumina collaborations—drew attention to the region. Over time the firm launched successive funds and engaged with organizations including the British Business Bank and private family offices to support translational research from institutions like the Wellcome Trust-funded centers and the Medical Research Council.

Investment strategy and focus

The firm's strategy targets capital-intensive translational opportunities emerging from the University of Cambridge, aiming to bridge gaps between academic research at institutions like the Cavendish Laboratory and commercial development in sectors such as biotechnology, quantum technology, and advanced materials. Investment theses incorporate technical due diligence with participation from domain experts connected to entities such as GlaxoSmithKline, AstraZeneca, and specialist research groups at St Catharine's College, Cambridge. The approach emphasizes follow-on funding for companies advancing from incubators like Cambridge Enterprise and accelerators linked to the Judge Business School, while aligning with policy initiatives involving the UK Research and Innovation framework and regional development bodies in Cambridgeshire.

Portfolio and notable investments

Portfolio companies span a range of life sciences and deep tech spinouts from Cambridge laboratories and hospitals. Notable investments include firms focused on genomics, synthetic biology, and photonics emerging from collaborations with research groups at EMBL-EBI, Sanger Institute, and the Cavendish Laboratory. The firm's portfolio has overlapped with companies that later engaged in rounds involving investors such as Sequoia Capital, Index Ventures, Accel Partners, and corporate venture arms of Microsoft, Google, and Johnson & Johnson. Exits and public listings in the broader Cambridge ecosystem—comparable to historical trajectories of Abcam and ARM Holdings—inform the firm's selection criteria and support for commercialization pathways, including licensing negotiations with pharmaceutical firms like Pfizer and strategic partnerships with industrial players like Schneider Electric.

Governance and management

Governance structures feature a board and investment committee drawing on expertise from figures with academic and entrepreneurial backgrounds linked to Hermann Hauser, alumni of the Cavendish Laboratory, and executives from multinational firms such as GlaxoSmithKline and AstraZeneca. Management includes investment partners who collaborate with technology transfer offices at institutions like Cambridge Enterprise and research institutes including the Babraham Institute and the Institute of Cancer Research. Advisory networks extend to bankers and legal counsel with experience in transactions at exchanges such as the London Stock Exchange and the NASDAQ, and to non-executive directors with prior roles at organizations like Imperial College London and the Wellcome Trust.

Financial performance and fundraising

Fundraising rounds have been positioned to attract commitments from sovereign wealth entities, family offices, and institutional investors comparable to participants in funds alongside the European Investment Fund and British Business Bank initiatives. Performance metrics emphasize internal rates of return and deployment velocity for seed through Series B rounds, informed by market comparables from successful Cambridge exits like Arm Holdings and later-stage financings involving global investors such as SoftBank Vision Fund and TPG Capital. The firm's ability to syndicate rounds with international investors and to participate in follow-on financing reflects experience navigating public markets and private placements involving advisors from firms like Goldman Sachs and Morgan Stanley.

Partnerships and ecosystem engagement

Cambridge Innovation Capital maintains partnerships with university commercialization offices, incubators, and research hospitals, aligning with entities such as Cambridge Enterprise, IdeaSpace, Addenbrooke's Hospital, and academic departments at the University of Cambridge. Ecosystem engagement includes collaboration with angel networks, accelerators like Entrepreneur First, and regional development programs in East of England, as well as participation in conferences and consortiums alongside institutions like the Wellcome Genome Campus and the European Molecular Biology Laboratory. These relationships support talent pipelines, translational projects, and strategic alliances with multinational corporations and public research funders.

Category:Venture capital firms of the United Kingdom Category:Companies based in Cambridge